Pharmaceuticals

Global Non-Viral Gene Delivery Technologies Market Projected to Expand at 15.2% CAGR by 2029

November 20, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Was The Non-Viral Gene Delivery Technologies Market Worth In 2025, And What Is Its Anticipated Value By 2029?

The non-viral gene delivery technologies market has experienced rapid expansion in recent years. It is projected to increase from $3.96 billion in 2024 to $4.57 billion in 2025, showing a compound annual growth rate (CAGR) of 15.6%. This historical growth can be attributed to the broadening scope of genetic research, the increasing prevalence of chronic genetic disorders, a rise in biotechnology and pharmaceutical research and development (R&D) activities, advancements in genetic and molecular biology research, and augmented government and institutional funding.

The non-viral gene delivery technologies market size is projected for significant expansion in the coming years. This market is anticipated to reach $8.06 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 15.2%. Factors driving this expansion during the forecast period include the increasing need for personalized medicine, greater utilization in cancer and rare disease investigations, the emergence of clustered regularly interspaced short palindromic repeats and gene editing technologies, swift progress in mRNA-based treatments, and the development of cell therapy and tissue engineering. Key trends expected during the forecast timeframe encompass improvements in lipid nanoparticles and polymer-based delivery systems, the evolution of deoxyribonucleic acid and ribonucleic acid therapeutics, incorporation with artificial intelligence and computational modeling, next-generation lipid nanoparticles (LNPs), and progress in nanotechnology.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27367&type=smp

What Are The Top Growth Drivers Impacting The Non-Viral Gene Delivery Technologies Market Outlook?

The future expansion of the non-viral gene delivery technologies market is anticipated to be fueled by the rising need for personalized medicine. Personalized medicine represents a healthcare strategy where prevention, diagnosis, and treatment are tailored according to an individual’s distinct genetic profile, lifestyle choices, and environmental factors. The escalating requirement for personalized medicine stems from progress in genomic sequencing technologies, enabling more precise diagnoses, specialized treatments, and better patient-specific therapeutic results. The heightened emphasis on personalized medicine is boosting the demand for non-viral gene delivery technologies, given their provision of safer and more flexible approaches for delivering therapeutic genes aligned with an individual’s genetic makeup, free from the hazards linked to viral vectors. As an illustration, in February 2024, data from the Personalized Medicine Coalition, a US-based non-profit organization, showed that the Food and Drug Administration (FDA) sanctioned 16 new personalized treatments for rare disease patients in 2023, an increase from 6 in 2022. Consequently, the expanding need for personalized medicine is stimulating the development of the non-viral gene delivery technologies market.

What Are The Major Segment Types Covered In The Non-Viral Gene Delivery Technologies Market?

The non-viral gene delivery technologies market covered in this report is segmented

1) By Product: Reagents And Kits, Delivery Devices, Pre-Formulated Nanoparticles

2) By Delivery: In-Vitro, In-Vivo, Ex-Vivo

3) By Technology: Electroporation, Lipid-Based Transfection, Polymer-Based Transfection, Physical Methods (Microinjection, Gene Gun), Nanoparticles

4) By Application: Gene Therapy, Deoxyribonucleic Acid (DNA) Vaccines, Ribonucleic Acid Interference (RNAi), Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or Cas9 Gene Editing, Protein Expression

5) By End-Use: Biotechnology And Biopharmaceutical Companies, Research And Academic Institutes, Other End-Uses

Subsegments:

1) By Reagents And Kits: Transfection Reagents, Plasmid Deoxyribonucleic Acid (DNA) Kits, Messenger Ribonucleic Acid (RNA) Delivery Kits, Small Interfering Ribonucleic Acid (RNA) Delivery Kits, Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein Reagents, Cell-Specific Delivery Reagents

2) By Delivery Devices: Electroporation Systems, Microinjection Systems, Gene Guns Or Biolistic Delivery Devices, Ultrasound-Mediated Delivery Devices, Hydrodynamic Gene Delivery Systems

3) By Pre-Formulated Nanoparticles: Lipid-Based Nanoparticles, Polymer-Based Nanoparticles, Gold-Based Nanoparticles, Dendrimer-Based Nanoparticles, Carbon Nanotube-Based Nanoparticles, Inorganic Compound-Based Nanoparticles

What Trends Are Redefining The Non-Viral Gene Delivery Technologies Market Dynamics?

Leading companies operating in the non-viral gene delivery market are concentrating on developing advanced solutions like non-viral genetic medicine platforms to improve the safety and efficiency of gene therapies. A non-viral genetic medicine platform is a technology designed to introduce therapeutic genes or nucleic acids into cells without using viruses, thereby reducing immune reactions and safety concerns, and enabling precise and controlled gene therapy delivery for a range of diseases. For instance, in October 2023, Generation Bio Co., a US-based biotechnology company focused on developing genetic medicines, introduced immune-quiet DNA (iqDNA). This novel DNA is an optimized variant of their closed-ended DNA (ceDNA) that skillfully evades innate immune detection, exhibiting cytokine levels and tolerability comparable to chemically modified mRNA in mice and non-human primates when delivered via their lipid nanoparticle (LNP) system. Due to iqDNA’s superior tolerability, Generation Bio is advancing this as the primary DNA cargo in all its programs, including its flagship hemophilia A program.

Which Leading Companies Dominate The Non-Viral Gene Delivery Technologies Market Share?

Major companies operating in the non-viral gene delivery technologies market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Evonik Industries AG, Moderna Inc., Boehringer Ingelheim GmbH, Agilent Technologies Inc., Lonza Group AG, Sartorius AG, Bio-Rad Laboratories Inc., Bio-Techne Corp., Takara Bio Inc., GenScript Biotech Corporation, Poseida Therapeutics Inc., ElevateBio LLC, ProBio Inc., ReCode Therapeutics Inc., Altogen Biosystems Inc., Generation Bio, Indee Labs Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/non-viral-gene-delivery-technologies-global-market-report

Which Regional Markets Are Contributing Most To The Non-Viral Gene Delivery Technologies Industry Expansion?

North America was the largest region in the non-viral gene delivery technologies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-viral gene delivery technologies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Non-Viral Gene Delivery Technologies Market Report:

https://www.thebusinessresearchcompany.com/customise?id=27367&type=smp

Browse Through More Reports Similar to the Global Non-Viral Gene Delivery Technologies Market 2025, By The Business Research Company

Low Density Polyethylene Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/low-density-polyethylene-global-market-report

Polyethylene Pipes Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/polyethylene-pipes-global-market-report

High Density Polyethylene Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/high-density-polyethylene-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795